Clinical Scorecard: Strategies for Combination Therapy to Address Resistance to Immune Checkpoint Inhibitors

At a Glance

Key Highlights

• Updated comprehensive list of FDA-approved ICI combination therapies as of July 2024
• Pembrolizumab combined with chemotherapy is FDA-approved for NSCLC treatment
• Correction ensures accurate reflection of FDA approvals and timing for combination therapies

Guideline-Based Recommendations

Diagnosis

• Identify cancer types eligible for FDA-approved ICI combination therapies
• Assess biomarkers such as dMMR and MSI status where relevant

Management

• Use FDA-approved ICI combinations tailored to specific cancer indications
• Incorporate chemotherapy with ICIs for NSCLC as per updated approvals

Monitoring & Follow-up

• Monitor treatment response and adverse effects during combination immunotherapy
• Adjust therapy based on clinical outcomes and emerging resistance

Risks

• Be aware of potential increased toxicity with combination regimens
• Consider immune-related adverse events associated with ICIs

Patient & Prescribing Data

Patients with cancers including NSCLC, TNBC, HNSCC, GEJ, ESCC, HCC, dMMR/MSI cancers, UC, RCC, and CRC

FDA approvals support use of specific ICI combinations, such as pembrolizumab plus chemotherapy in NSCLC, to improve outcomes and address resistance

Clinical Best Practices

• Refer to updated FDA-approved combination immunotherapy regimens as of July 2024
• Ensure accurate patient selection based on cancer type and biomarker status
• Stay informed on evolving approvals and clinical evidence for ICI combinations

References

• Correction Article on Combination Therapy Strategies